Compare VHC & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHC | MXCT |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 93.0M |
| IPO Year | 2008 | 2021 |
| Metric | VHC | MXCT |
|---|---|---|
| Price | $18.04 | $1.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 12.7K | ★ 1.2M |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $162,000.00 | ★ $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3140.00 | N/A |
| 52 Week Low | $6.60 | $0.64 |
| 52 Week High | $29.00 | $2.40 |
| Indicator | VHC | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 67.08 | 73.83 |
| Support Level | $15.94 | $0.72 |
| Resistance Level | $18.32 | $1.75 |
| Average True Range (ATR) | 1.12 | 0.10 |
| MACD | 0.48 | 0.02 |
| Stochastic Oscillator | 100.00 | 95.88 |
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.